Radiopharmaceutical | AInj,37 (kBq) | D(marrow)/AInj* (cGy/kBq) | RAF† | RAF‡ | τ(muscle)§ (h) |
---|---|---|---|---|---|
32P-orthophosphate¶ | 313 ± 29 | 0.42 ± 0.055 | — | — | 3.7 |
33P-orthophosphate¶ | 2820 ± 425 | 0.047 ± 0.010 | 4.2 | 5.6 | 5.3 |
117mSn(4+)DTPA | 3546 ± 88 | 0.043 ± 0.002 | 8.2 | 5.5 | 0.0693 |
↵* Experimental mean absorbed dose to femoral marrow per unit injected activity.
↵† Relative advantage factor based on experimental D(marrow)/AInj and theoretic D(matrix)/AInj.
↵‡ Relative advantage factor based on theoretic D(marrow)/AInj and theoretic D(matrix)/AInj.
↵§ Residence time in muscle after integrating to ∞.
↵¶ Data taken from (20).